Episode 18: A Between the Biotech Waves conversation with Ram Aiyer, CEO of RNA base editing company Korro Bio
Between the Biotech Waves
00:00
Do You Have a Long Term Vision for Coro?
I think building the company around going after prevalent indication and the first wave being ADAR, you hit it on the nail. I think that when you think about this technology, what we'll end up doing is giving confidence to patients and physicians in terms of these are the changes we're making. These are the thresholds we need to achieve despite the diversity in the patient population. And if you can then come on top with a permanent edit, yes, it'll take a little bit time. But fundamentally, I think building a company aroundgoing after both of those components or all of those components, I think is in the future of Coro.
Transcript
Play full episode
